Genmab A/S Files 6-K for S-8 Registration Statements
Ticker: GNMSF · Form: 6-K · Filed: Jul 17, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Jul 17, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, stock-incentive-plan, registration-statement
TL;DR
Genmab filed a 6-K, updating its S-8 filings for stock incentive plans. No new shares, just housekeeping.
AI Summary
Genmab A/S filed a Form 6-K on July 17, 2024, to be incorporated by reference into its existing S-8 registration statements. These statements relate to the company's stock incentive plans, specifically referencing file numbers 333-232693, 333-253519, 333-262970, and 333-277273.
Why It Matters
This filing ensures that Genmab's stock incentive plans remain current and compliant with SEC regulations, impacting the administration and availability of shares for employee compensation.
Risk Assessment
Risk Level: low — This is a routine administrative filing related to existing stock incentive plans and does not introduce new financial or operational risks.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 333-232693 (registration_statement) — S-8 File Number
- 333-253519 (registration_statement) — S-8 File Number
- 333-262970 (registration_statement) — S-8 File Number
- 333-277273 (registration_statement) — S-8 File Number
FAQ
What is the purpose of this Form 6-K filing by Genmab A/S?
The Form 6-K is filed to be incorporated by reference into Genmab A/S's existing registration statements on Form S-8, which relate to its stock incentive plans.
Which specific Form S-8 registration statements are affected by this filing?
This filing is incorporated into Form S-8 registration statements with file numbers 333-232693, 333-253519, 333-262970, and 333-277273.
What is the filing date of this Form 6-K?
The filing date is July 17, 2024.
Does this filing introduce new stock incentive plans?
No, the filing states it is incorporated by reference into existing registration statements, implying it pertains to the administration or updates of current plans rather than the introduction of new ones.
What is the principal executive office address of Genmab A/S?
The principal executive offices are located at Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Filing Stats: 227 words · 1 min read · ~1 pages · Grade level 14.9 · Accepted 2024-07-17 10:00:41
Filing Documents
- tmb-20240717x6k.htm (6-K) — 18KB
- tmb-20240717xex99d1.htm (EX-99.1) — 24KB
- tmb-20240717xex99d1001.jpg (GRAPHIC) — 5KB
- 0001558370-24-009859.txt ( ) — 50KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JULY 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: JULY 17, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated July 17, 2024: Genmab Announces Net Sales of DARZALEX (daratumumab) for Second Quarter of 2024